Limits...
Assessment of Growth Disturbance in Japanese Children with IBD.

Shono T, Kato M, Aoyagi Y, Haruna H, Fujii T, Kudo T, Ohtsuka Y, Shimizu T - Int J Pediatr (2010)

Bottom Line: We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18).Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance.Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

ABSTRACT
In Japan, there is as yet no report on growth retardation in children with IBD. We therefore investigated the cause of growth retardation in Japanese children with IBD. We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18). Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance. Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

No MeSH data available.


Related in: MedlinePlus

Comparison of growth rate SDS between children with CD and those with UC during the 1-year period before the initial assessment and the 1-year period subsequent to the initial assessment. before: 1 year to initial visit; after: from initial visit to 1 year later.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2864444&req=5

fig1: Comparison of growth rate SDS between children with CD and those with UC during the 1-year period before the initial assessment and the 1-year period subsequent to the initial assessment. before: 1 year to initial visit; after: from initial visit to 1 year later.

Mentions: There was a significant increase in the growth rate SDS in children with CD (P < .05) but a significant decrease in children with UC (P < .05) when we compared the growth rate during the 1-year period before the start of treatment with the growth rate during the 1-year period subsequent to treatment (Figure 1). Compared with the 1-year period before the start of treatment, height SDS in children with CD at diagnosis was significantly lower (P < .05); however, there was no significant difference between the pretreatment level and the level 1 year subsequent to the start of treatment. On the other hand, in children with UC, there was no significant difference in height SDS when comparisons were made between values obtained 1 year before the start of treatment, at diagnosis, and 1 year subsequent to the start of treatment (Figure 2).


Assessment of Growth Disturbance in Japanese Children with IBD.

Shono T, Kato M, Aoyagi Y, Haruna H, Fujii T, Kudo T, Ohtsuka Y, Shimizu T - Int J Pediatr (2010)

Comparison of growth rate SDS between children with CD and those with UC during the 1-year period before the initial assessment and the 1-year period subsequent to the initial assessment. before: 1 year to initial visit; after: from initial visit to 1 year later.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2864444&req=5

fig1: Comparison of growth rate SDS between children with CD and those with UC during the 1-year period before the initial assessment and the 1-year period subsequent to the initial assessment. before: 1 year to initial visit; after: from initial visit to 1 year later.
Mentions: There was a significant increase in the growth rate SDS in children with CD (P < .05) but a significant decrease in children with UC (P < .05) when we compared the growth rate during the 1-year period before the start of treatment with the growth rate during the 1-year period subsequent to treatment (Figure 1). Compared with the 1-year period before the start of treatment, height SDS in children with CD at diagnosis was significantly lower (P < .05); however, there was no significant difference between the pretreatment level and the level 1 year subsequent to the start of treatment. On the other hand, in children with UC, there was no significant difference in height SDS when comparisons were made between values obtained 1 year before the start of treatment, at diagnosis, and 1 year subsequent to the start of treatment (Figure 2).

Bottom Line: We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18).Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance.Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

ABSTRACT
In Japan, there is as yet no report on growth retardation in children with IBD. We therefore investigated the cause of growth retardation in Japanese children with IBD. We investigated the height, body weight, serum levels of albumin, IGF-I, CRP, and cytokines, and the amount of corticosteroid administered in children with Crohn's disease (CD, n = 15) and ulcerative colitis (UC, n = 18). Our results suggest that growth retardation is already present before the initial visit in children with CD, and chronic inflammation may be responsible this growth disturbance. Moreover, the amount of PSL used may contribute to growth retardation by decreasing the serum levels of IGF-I in children with IBD.

No MeSH data available.


Related in: MedlinePlus